

## Valeant Announces Q2 2017 Financial Results Date And Conference Call Details

July 10, 2017

LAVAL, Quebec, July 10, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it plans to release second quarter 2017 financial results on Tuesday, Aug. 8, 2017. The Company will host a conference call and live webcast at 8:00 a.m. EDT to discuss the results and provide a business update. All materials will be made available on the investor relations portion of the corporate website before the start of the conference call.

### Conference Call Details

Date	Tuesday, Aug. 8, 2017
------	-----------------------

Time	8:00 a.m. EDT
------	---------------

Webcast	<a href="http://ir.valeant.com/events-and-presentations">http://ir.valeant.com/events-and-presentations</a>
---------	-------------------------------------------------------------------------------------------------------------

Participant Event Dial-in	(877) 876-8393 (North America)
---------------------------	--------------------------------

	(443) 961-0178 (International)
--	--------------------------------

Participant Passcode	35736021
----------------------	----------

Replay Dial-in	(855) 859-2056 (North America)
----------------	--------------------------------

	(404) 537-3406 (International)
--	--------------------------------

Replay Passcode	31833 (replay available until Oct. 8, 2017)
-----------------	---------------------------------------------

### About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at [www.valeant.com](http://www.valeant.com)

## Investor Contacts:

Arthur Shannon

Elif McDonald

[arthur.shannon@valeant.com](mailto:arthur.shannon@valeant.com)

[elif.mcdonald@valeant.com](mailto:elif.mcdonald@valeant.com)

514-856-3855

514-856-3855

877-281-6642 (toll free)

877-281-6642 (toll free)

## Media Contact:

Lainie Keller

[lainie.keller@valeant.com](mailto:lainie.keller@valeant.com)

908-927-0617

View original content with multimedia:

<http://www.prnewswire.com/news-releases/valeant-announces-q2-2017-financial-results-date-and-conference-call-details-300485451.html>

SOURCE Valeant Pharmaceuticals International, Inc.



### Investor Inquiries

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)

877-281-6642

514-856-3855 (Canada)

### Media inquiries

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)

908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.  
©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION**